CYP2S1

Across TCGA pan-cancer cohorts, CYP2S1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CYP2S1 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CYP2S1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CYP2S1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

STAD, GBM, and BLCA are the cancer types where CYP2S1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	1.000	0.382	.028	14	view →
GBM	DFS	Median	All	0.043	0.243	.003	6	view →
BLCA	OS	Median	All	0.188	0.687	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CYP2S1–STAD (DFS)

Open the STAD breakdown →